Table 1.
Patient and tumor characteristics
| Characteristics | Whole patients (n=756) | % | Without recurrence (n=690) | % | Recurrence (n=66) | % | p |
|---|---|---|---|---|---|---|---|
| Age (years) | |||||||
| <65 | 654 | 86.50% | 604 | 87.50% | 50 | 75.80% | 0.01 |
| ≥65 | 102 | 13.50% | 86 | 12.50% | 16 | 24.20% | |
| Pathological type | |||||||
| Type 1 | 716 | 94.70% | 655 | 94.90% | 61 | 92.40% | 0.383 |
| Type 2 | 40 | 5.30% | 35 | 5.10% | 5 | 7.60% | |
| Grade† | |||||||
| 1 | 308 | 40.70% | 296 | 42.90% | 12 | 18.20% | <0.001 |
| 2 | 317 | 41.90% | 286 | 41.40% | 31 | 47.00% | |
| 3 | 109 | 14.40% | 90 | 13.00% | 19 | 28.80% | |
| LVSI | |||||||
| Yes | 135 | 17.90% | 120 | 17.40% | 15 | 22.70% | 0.312 |
| No | 621 | 82.10% | 570 | 82.60% | 51 | 77.30% | |
| FIGO stage | |||||||
| Ia | 410 | 54.20% | 383 | 55.50% | 27 | 40.90% | <0.001 |
| Ib | 304 | 40.20% | 276 | 40% | 28 | 42.40% | |
| II | 42 | 5.60% | 31 | 4.50% | 11 | 16.70% | |
| Risk stratification | |||||||
| Low risk | 272 | 36.00% | 259 | 37.50% | 13 | 19.70% | <0.001 |
| Intermediate risk | 220 | 29.10% | 204 | 29.60% | 16 | 24.20% | |
| High-intermediate risk | 155 | 20.50% | 137 | 19.90% | 18 | 27.30% | |
| High risk | 109 | 14.40% | 90 | 13.00% | 19 | 28.80% | |
| Prior treatment regimen | <0.001 | ||||||
| VBT alone | 481 | 63.60% | 449 | 65.10% | 32 | 48.50% | |
| EBRT ± VBT | 187 | 24.70% | 169 | 24.50% | 18 | 27.30% | |
| VBT + chemo | 29 | 3.80% | 25 | 3.60% | 4 | 6.10% | |
| EBRT ± VBT+ chemo | 59 | 7.80% | 47 | 6.80% | 12 | 18.20% |
Abbreviations: EEC: endometrioid endometrial carcinoma; LVSI, lymph-vascular space invasion. Chemo: chemotherapy. FIGO: International Federation of Gynecology and Obstetrics; VBT: vaginal brachytherapy; EBRT: external beam radiotherapy; chemo: chemotherapy.
Note: Grade†: Non-endometrioid endometrial types were excluded from this group. Bold indicates p-Value <0.05, considered significant.